We design and develop a new class of powerful therapeutics for the treatment of severe diseases. Our plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2011
  • Number of employees in Switzerland
    20-49
Key business